semaglutide glp 1 analogue Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit PDB-101: Diabetes Mellitus: Diabetes Mellitus:

Learn more With Faire, shop unique wholesale products for your store from brands like Healthogenics and more

Do not make the mistake of thinking that taking a couple of supplements will help you lose weight because that is not the case

H, hypothalamus

If retatrutide follows the typical regulatory pathway, a first approval for obesity could arrive in 2026 or 2027

Phase 3 Update: TRIUMPH-4 Results Preliminary data from the ongoing Phase 3 TRIUMPH-4 trial (68 weeks) shows higher numbers than Phase 2: 12mg dose: 28.7% average weight loss (~71 lbs / 32 kg) 9mg dose: 26.4% average weight loss (~64 lbs / 29 kg) Knee osteoarthritis pain: 76% reduction (significant quality-of-life improvement) Blood pressure: Average reduction of 14 mmHg Full Phase 3 results across the TRIUMPH program (obesity, diabetes, cardiovascular outcomes, kidney outcomes) are expected throughout 2026